Switch theme
Sign up to access all valuation multiples
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
2014
506
LTM Revenue $125M
LTM EBITDA -$79.9M
$65.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adaptimmune Therapeutics has a last 12-month revenue (LTM) of $125M and a last 12-month EBITDA of -$79.9M.
In the most recent fiscal year, Adaptimmune Therapeutics achieved revenue of $178M and an EBITDA of -$52.7M.
Adaptimmune Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adaptimmune Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $125M | XXX | $178M | XXX | XXX | XXX |
| Gross Profit | $121M | XXX | $178M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$79.9M | XXX | -$52.7M | XXX | XXX | XXX |
| EBITDA Margin | -64% | XXX | -30% | XXX | XXX | XXX |
| EBIT | -$94.5M | XXX | -$52.4M | XXX | XXX | XXX |
| EBIT Margin | -76% | XXX | -29% | XXX | XXX | XXX |
| Net Profit | -$96.9M | XXX | -$70.8M | XXX | XXX | XXX |
| Net Margin | -78% | XXX | -40% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Adaptimmune Therapeutics's stock price is $0.
Adaptimmune Therapeutics has current market cap of $76.4M, and EV of $65.6M.
See Adaptimmune Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $65.6M | $76.4M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Adaptimmune Therapeutics has market cap of $76.4M and EV of $65.6M.
Adaptimmune Therapeutics's trades at 0.4x EV/Revenue multiple, and -1.2x EV/EBITDA.
Equity research analysts estimate Adaptimmune Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adaptimmune Therapeutics has a P/E ratio of -0.8x.
See valuation multiples for Adaptimmune Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $76.4M | XXX | $76.4M | XXX | XXX | XXX |
| EV (current) | $65.6M | XXX | $65.6M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 0.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAdaptimmune Therapeutics's last 12 month revenue growth is -54%
Adaptimmune Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Adaptimmune Therapeutics's rule of 40 is -266% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Adaptimmune Therapeutics's rule of X is -198% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Adaptimmune Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -54% | XXX | -37% | XXX | XXX | XXX |
| EBITDA Margin | -64% | XXX | -30% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -266% | XXX | -83% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -198% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 129% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adaptimmune Therapeutics acquired XXX companies to date.
Last acquisition by Adaptimmune Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Adaptimmune Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Adaptimmune Therapeutics founded? | Adaptimmune Therapeutics was founded in 2014. |
| Where is Adaptimmune Therapeutics headquartered? | Adaptimmune Therapeutics is headquartered in United States of America. |
| How many employees does Adaptimmune Therapeutics have? | As of today, Adaptimmune Therapeutics has 506 employees. |
| Who is the CEO of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's CEO is Mr. Adrian Rawcliffe. |
| Is Adaptimmune Therapeutics publicy listed? | Yes, Adaptimmune Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Adaptimmune Therapeutics? | Adaptimmune Therapeutics trades under ADAP ticker. |
| When did Adaptimmune Therapeutics go public? | Adaptimmune Therapeutics went public in 2015. |
| Who are competitors of Adaptimmune Therapeutics? | Similar companies to Adaptimmune Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's current market cap is $76.4M |
| What is the current revenue of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's last 12 months revenue is $125M. |
| What is the current revenue growth of Adaptimmune Therapeutics? | Adaptimmune Therapeutics revenue growth (NTM/LTM) is -54%. |
| What is the current EV/Revenue multiple of Adaptimmune Therapeutics? | Current revenue multiple of Adaptimmune Therapeutics is 0.5x. |
| Is Adaptimmune Therapeutics profitable? | Yes, Adaptimmune Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's last 12 months EBITDA is -$79.9M. |
| What is Adaptimmune Therapeutics's EBITDA margin? | Adaptimmune Therapeutics's last 12 months EBITDA margin is -64%. |
| What is the current EV/EBITDA multiple of Adaptimmune Therapeutics? | Current EBITDA multiple of Adaptimmune Therapeutics is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
